Cadrenal Therapeutics Inc
cadrenal.comWhat Do They Do?
Develops drug candidates for people with immune and thrombotic conditions, including a treatment for heparin-induced thrombocytopenia, an anticoagulant for chronic use, and an injectable anticoagulant for acute care.
10-K for FY2025, filed Mar 31, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$3.3MView ↗
- ▼ −9% (Loss)
- vs −$3.7M in Q2 FY2025
-
Aug 31, 2026
FDA aligns with Cadrenal on key Phase 3 trial design elements
The agency agreed on the primary endpoint definition and placebo control, with standard anticoagulants in both trial arms.
Sources
8-K, filed Aug 31, 2026
On August 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) issued a press release announcing positive feedback from a Type D Meeting…View ↗
Broader drug pipeline
The earlier report centered on tecarfarin for chronic anticoagulation in patients with kidney disease and atrial fibrillation. The latest report adds an immune-thrombosis drug candidate and an acute-care anticoagulant candidate, and makes treatment of heparin-induced thrombocytopenia its primary focus.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result…View ↗
Our broader pipeline includes two additional clinical-stage assets—tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist…View ↗
Our overarching goal at Cadrenal is to advance novel therapies for life-threatening immune and thrombotic conditions. Our current primary…View ↗
Loading...
